Zhu Andy Z X, Zhou Qian, Cox Lisa Sanderson, Ahluwalia Jasjit S, Benowitz Neal L, Tyndale Rachel F
Departments of Pharmacology and Toxicology (A.Z.X.Z., Q.Z., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Ontario, Canada; Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, Kansas (L.S.C.); Department of Medicine and Center for Health Equity, University of Minnesota Medical School, Minneapolis, Minnesota (J.S.A.); Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering & Therapeutic Sciences, University of California, San Francisco, California (N.L.B.); and Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health, Toronto, Ontario, Canada (R.F.T.).
Departments of Pharmacology and Toxicology (A.Z.X.Z., Q.Z., R.F.T.) and Department of Psychiatry (R.F.T.), University of Toronto, Ontario, Canada; Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, Kansas (L.S.C.); Department of Medicine and Center for Health Equity, University of Minnesota Medical School, Minneapolis, Minnesota (J.S.A.); Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering & Therapeutic Sciences, University of California, San Francisco, California (N.L.B.); and Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health, Toronto, Ontario, Canada (R.F.T.)
Drug Metab Dispos. 2014 Nov;42(11):1971-7. doi: 10.1124/dmd.114.060285. Epub 2014 Sep 3.
Bupropion is used clinically to treat depression and to promote smoking cessation. It is metabolized by CYP2B6 to its active metabolite hydroxybupropion, yet alterations in CYP2B6 activity have little impact on bupropion plasma levels. Furthermore, less than 10% of a bupropion dose is excreted as urinary bupropion and its characterized metabolites hydroxybupropion, threohydrobupropion, and erythrohydrobupropion, suggesting that alternative metabolic pathways may exist. In vitro data suggested CYP2C19 could metabolize bupropion. The current study investigated the impact of functional CYP2C19 genetic variants on bupropion pharmacokinetics and treatment outcomes. In 42 healthy volunteers, CYP2C192 (a reduced activity allele) was associated with higher bupropion area under the plasma concentration-time curve (AUC), but similar hydroxybupropion AUC. The mean bupropion AUC was 771 versus 670 hours⋅ng/ml in individuals with and without CYP2C192, respectively (P = 0.017). CYP2C19*2 was also associated with higher threohydrobupropion and erythrohydrobupropion AUC (P < 0.005). Adjusting for CYP2B6 genotype did not alter these associations, and CYP2C19 variants did not alter the utility of the hydroxybupropion/bupropion ratio as a measure of CYP2B6 activity. Finally, in a clinical trial of 540 smokers, CYP2C19 genotype was not associated with smoking cessation outcomes, supporting the hypothesis that bupropion response is mediated by hydroxybupropion, which is not altered by CYP2C19. In conclusion, our study reports the first in vivo evidence that reduced CYP2C19 activity significantly increases the steady-state exposure to bupropion and its reductive metabolites threohydrobupropion and erythrohydrobupropion. These pharmacokinetic changes were not associated with differences in bupropion's ability to promote smoking cessation in smokers, but may influence the side effects and toxicity associated with bupropion.
安非他酮临床上用于治疗抑郁症和促进戒烟。它经细胞色素P450 2B6(CYP2B6)代谢为其活性代谢产物羟基安非他酮,然而CYP2B6活性的改变对安非他酮血浆水平影响很小。此外,安非他酮剂量中不到10%以尿安非他酮及其特征性代谢产物羟基安非他酮、苏式羟基安非他酮和赤式羟基安非他酮的形式排泄,这表明可能存在其他代谢途径。体外数据表明CYP2C19可代谢安非他酮。本研究调查了功能性CYP2C19基因变异对安非他酮药代动力学和治疗结果的影响。在42名健康志愿者中,CYP2C192(一种活性降低的等位基因)与安非他酮血浆浓度-时间曲线下面积(AUC)较高有关,但羟基安非他酮AUC相似。有和没有CYP2C192的个体中,安非他酮的平均AUC分别为771和670小时·纳克/毫升(P = 0.017)。CYP2C19*2也与苏式羟基安非他酮和赤式羟基安非他酮的较高AUC有关(P < 0.005)。校正CYP2B6基因型并没有改变这些关联,并且CYP2C19变异并没有改变羟基安非他酮/安非他酮比值作为CYP2B6活性指标的效用。最后,在一项针对540名吸烟者的临床试验中,CYP2C19基因型与戒烟结果无关,支持了安非他酮反应由羟基安非他酮介导这一假说,而羟基安非他酮不会因CYP2C19而改变。总之,我们的研究首次报告了体内证据,即CYP2C19活性降低会显著增加安非他酮及其还原代谢产物苏式羟基安非他酮和赤式羟基安非他酮的稳态暴露量。这些药代动力学变化与安非他酮促进吸烟者戒烟能力的差异无关,但可能会影响与安非他酮相关的副作用和毒性。